In this preprint, Hassan et al. show that local immunization with the ChAd-SARS-CoV-2-S vaccine, based on a chimpanzee adenovirus, confers sterilizing protection in mice engineered to express human ACE2. Intramuscular delivery of ChAd-SARS-CoV-2-S protected against lung pathology but did not clear the infection of the upper respiratory tract after SARS-CoV-2 challenge. However, when administered intranasally, it induced local neutralizing antibody and T cell responses that provided superior protection to both the upper and lower respiratory tract, with no signs of viral replication 8 days post viral challenge. The presence of tissue-resident memory T cells in the lung suggested long-lasting protection. This work illustrates the importance of the delivery route to vaccine effectivity.
References
Original article
Hassan, A. O. et al. A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection. Preprint at bioRxiv https://doi.org/10.1101/2020.07.16.205088 (2020)
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Gea-Mallorquí, E., Compeer, E.B. SARS-CoV-2 vaccine — think globally, act locally. Nat Rev Immunol 20, 590 (2020). https://doi.org/10.1038/s41577-020-00422-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-00422-w
